Pamicell Sees Strong Demand for Nucleoside Supply

[Asia Economy Reporter Hyungsoo Park] Pharmicell announced on the 19th that it received an order worth $1.57 million (approximately 1.9 billion KRW) for nucleosides from ThermoFisher Scientific in the United States.

A company official stated, "Demand for ThermoFisher products has increased due to the establishment of a global supply chain and the full-scale development of nucleic acid therapeutics using RNA, leading to a rise in demand for nucleosides."

In particular, the official added, "With this order, we expect nucleoside sales to exceed 2.5 billion KRW in the first quarter of last year," and "We anticipate significant growth this year as well."

Nucleosides are units that make up nucleic acids and are used as raw materials for genetic diagnostic reagents (various virus diagnostic kits) and new gene therapy drugs. Pharmicell's nucleosides have been recognized for their technology and production capacity and are supplied to major companies in the United States and Europe. They hold more than 80% of the global market for diagnostic and pharmaceutical nucleosides.

ThermoFisher processes the nucleosides received from Pharmicell and supplies them to pharmaceutical companies and research institutes worldwide.

This content was produced with the assistance of AI translation services.